Drug intelligence / Profile preview

BMS-986337

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986337 is an investigational small molecule drug developed by Bristol Myers Squibb. It acts as an antagonist of the lysophosphatidic acid receptor 1 (LPAR1), also known as Edg-2. The drug is being studied for its potential use in treating idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and loss of elasticity in the lungs, which can lead to respiratory failure. Elevated levels of lysophosphatidic acid (LPA) have been observed in IPF patients, where LPA contributes to abnormal wound healing and fibrosis. By blocking LPAR1, BMS-986337 may help modulate these pathological processes and offer therapeutic benefit for IPF patients.

Targets

LPAR1 (Lysophosphatidic acid receptor 1)

Beyond the preview

Go deeper on BMS-986337.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986337.

Explore the full profile